The ability to extract insights from big data is quickly becoming a key factor for competitive advantage in every industry, and Life Sciences is no different.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh